PROC抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: SKOV3 cell lysate, Primary antibody: P06441(PROC Antibody) at dilution 1/1300, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P06441(PROC Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06441(PROC Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

PROC antibodies target protein C, a vitamin K-dependent glycoprotein synthesized in the liver and crucial for regulating blood coagulation. Protein C, when activated by thrombin-thrombomodulin complexes, becomes activated protein C (APC), which inactivates coagulation factors Va and VIIIa, thereby inhibiting excessive clot formation and promoting fibrinolysis. PROC antibodies are associated with acquired protein C deficiency, often linked to autoimmune conditions, infections, or malignancies. These autoantibodies may neutralize protein C’s activity or accelerate its clearance, leading to a hypercoagulable state.

Clinically, PROC antibody-related disorders manifest as recurrent venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism) or purpura fulminans in severe cases. They are frequently observed in autoimmune diseases like antiphospholipid syndrome (APS) or systemic lupus erythematosus (SLE). Detection involves immunoassays to identify antibodies and functional tests to assess protein C activity. Management includes anticoagulation (e.g., heparin, direct oral anticoagulants) and immunosuppressive therapies to address underlying autoimmune triggers. Research continues to clarify the pathogenic mechanisms and optimize diagnostic and therapeutic strategies for these rare but potentially life-threatening conditions.